vs
LIGAND PHARMACEUTICALS INC（LGND）与万物新生（RERE）财务数据对比。点击上方公司名可切换其他公司
LIGAND PHARMACEUTICALS INC的季度营收约是万物新生的1.4倍（$59.7M vs $43.2M），LIGAND PHARMACEUTICALS INC净利率更高（75.1% vs 16.9%，领先58.2%）
利根制药是美国的生物制药企业，专注于收购和开发可产生特许权使用费的资产。截至2024年，公司的资产组合涵盖约90款覆盖多个治疗领域的药品的特许权使用权，可从多发性骨髓瘤治疗药物凯洛斯、Evomela，肾病治疗药物Filspari，以及肺炎球菌疫苗Vaxneuvance等知名产品中获得相关收益。
万物新生集团（ATRenew Inc.）是中国领先的二手消费电子产品交易与服务平台运营商，核心业务覆盖数码产品回收、质检、翻新及售卖，运营有爱回收等知名品牌，服务覆盖个人消费者及企业客户，市场遍及国内及部分东南亚地区。
LGND vs RERE — 直观对比
营收规模更大
LGND
是对方的1.4倍
$43.2M
净利率更高
LGND
高出58.2%
16.9%
损益表 — Q4 FY2025 vs Q1 FY2023
| 指标 | | |
|---|---|---|
| 营收 | $59.7M | $43.2M |
| 净利润 | $44.8M | $7.3M |
| 毛利率 | — | — |
| 营业利润率 | 23.2% | — |
| 净利率 | 75.1% | 16.9% |
| 营收同比 | 39.4% | — |
| 净利润同比 | 244.1% | — |
| 每股收益（稀释后） | $2.42 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LGNDRERE
| Q4 25 | $59.7M | — | ||
| Q3 25 | $115.5M | — | ||
| Q2 25 | $47.6M | — | ||
| Q1 25 | $45.3M | — | ||
| Q4 24 | $42.8M | — | ||
| Q3 24 | $51.8M | — | ||
| Q2 24 | $41.5M | — | ||
| Q1 24 | $31.0M | — |
净利润LGNDRERE
| Q4 25 | $44.8M | — | ||
| Q3 25 | $117.3M | — | ||
| Q2 25 | $4.8M | — | ||
| Q1 25 | $-42.5M | — | ||
| Q4 24 | $-31.1M | — | ||
| Q3 24 | $-7.2M | — | ||
| Q2 24 | $-51.9M | — | ||
| Q1 24 | $86.1M | — |
营业利润率LGNDRERE
| Q4 25 | 23.2% | — | ||
| Q3 25 | 47.6% | — | ||
| Q2 25 | 17.7% | — | ||
| Q1 25 | -79.9% | — | ||
| Q4 24 | -22.5% | — | ||
| Q3 24 | 6.1% | — | ||
| Q2 24 | -46.0% | — | ||
| Q1 24 | 9.6% | — |
净利率LGNDRERE
| Q4 25 | 75.1% | — | ||
| Q3 25 | 101.6% | — | ||
| Q2 25 | 10.2% | — | ||
| Q1 25 | -93.6% | — | ||
| Q4 24 | -72.6% | — | ||
| Q3 24 | -13.8% | — | ||
| Q2 24 | -125.0% | — | ||
| Q1 24 | 278.1% | — |
每股收益（稀释后）LGNDRERE
| Q4 25 | $2.42 | — | ||
| Q3 25 | $5.68 | — | ||
| Q2 25 | $0.24 | — | ||
| Q1 25 | $-2.21 | — | ||
| Q4 24 | $-1.70 | — | ||
| Q3 24 | $-0.39 | — | ||
| Q2 24 | $-2.88 | — | ||
| Q1 24 | $4.75 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $733.5M | $228.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.0B | $557.1M |
| 总资产 | $1.6B | $722.9M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资LGNDRERE
| Q4 25 | $733.5M | — | ||
| Q3 25 | $664.5M | — | ||
| Q2 25 | $245.0M | — | ||
| Q1 25 | $208.9M | — | ||
| Q4 24 | $256.2M | — | ||
| Q3 24 | $219.6M | — | ||
| Q2 24 | $226.9M | — | ||
| Q1 24 | $310.6M | — |
股东权益LGNDRERE
| Q4 25 | $1.0B | — | ||
| Q3 25 | $950.2M | — | ||
| Q2 25 | $828.5M | — | ||
| Q1 25 | $795.5M | — | ||
| Q4 24 | $830.4M | — | ||
| Q3 24 | $841.2M | — | ||
| Q2 24 | $775.2M | — | ||
| Q1 24 | $806.5M | — |
总资产LGNDRERE
| Q4 25 | $1.6B | — | ||
| Q3 25 | $1.5B | — | ||
| Q2 25 | $948.6M | — | ||
| Q1 25 | $905.4M | — | ||
| Q4 24 | $941.8M | — | ||
| Q3 24 | $954.9M | — | ||
| Q2 24 | $866.4M | — | ||
| Q1 24 | $913.9M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.9M | — |
| 自由现金流经营现金流 - 资本支出 | $45.9M | — |
| 自由现金流率自由现金流/营收 | 76.9% | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | 1.03× | — |
| 过去12个月自由现金流最近4个季度 | $48.9M | — |
8季度趋势，按日历期对齐
经营现金流LGNDRERE
| Q4 25 | $45.9M | — | ||
| Q3 25 | $13.1M | — | ||
| Q2 25 | $15.8M | — | ||
| Q1 25 | $-25.4M | — | ||
| Q4 24 | $28.5M | — | ||
| Q3 24 | $36.5M | — | ||
| Q2 24 | $13.3M | — | ||
| Q1 24 | $18.7M | — |
自由现金流LGNDRERE
| Q4 25 | $45.9M | — | ||
| Q3 25 | $13.1M | — | ||
| Q2 25 | $15.6M | — | ||
| Q1 25 | $-25.7M | — | ||
| Q4 24 | $27.8M | — | ||
| Q3 24 | $35.9M | — | ||
| Q2 24 | $12.9M | — | ||
| Q1 24 | $18.6M | — |
自由现金流率LGNDRERE
| Q4 25 | 76.9% | — | ||
| Q3 25 | 11.3% | — | ||
| Q2 25 | 32.7% | — | ||
| Q1 25 | -56.6% | — | ||
| Q4 24 | 64.8% | — | ||
| Q3 24 | 69.4% | — | ||
| Q2 24 | 31.1% | — | ||
| Q1 24 | 60.1% | — |
资本支出强度LGNDRERE
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.4% | — | ||
| Q1 25 | 0.5% | — | ||
| Q4 24 | 1.7% | — | ||
| Q3 24 | 1.2% | — | ||
| Q2 24 | 1.0% | — | ||
| Q1 24 | 0.3% | — |
现金转化率LGNDRERE
| Q4 25 | 1.03× | — | ||
| Q3 25 | 0.11× | — | ||
| Q2 25 | 3.26× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.22× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LGND
| Intangible Royalty Assets | $40.7M | 68% |
| Financial Royalty Assets | $9.8M | 16% |
| Material Sales Captisol | $7.8M | 13% |
| Vaxneuvance | $1.4M | 2% |
RERE
暂无分部数据
